Merck reports tulisokibart results for Merck & Co. stock

Published on 10/01/2026 at 12:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 16.61 billion, up 5.10 percent year over year. Merck & Co. stock costs EUR 128.34 on October 1, 2026, versus EUR 128.39.

Photorealistic wide-angle view of a modern oncology research laboratory. A scientist in white lab coat examines cancer cell slides under a fluorescence microscope. Amber glass vials with pharmaceutical compounds line the stainless steel bench. Biosafety c — Merck US58933Y1055 Onkologie-Labor: Wissenschaftler am Mikroskop analysiert Krebszellen, mehrere Wirkstoff-Vials stehen auf der Werkbank, Illustration mit AI erstellt.

Merck & Co. stock (ISIN US58933Y1055) was trading at EUR 128.34 at Lang & Schwarz on October 1, 2026 at 12:03 p.m. CEST, minus 0.04 percent versus the prior close of EUR 128.39. According to Merck on September 30, 2026, tulisokibart met its primary and key secondary endpoints in a Phase 2b study for moderate to severe hidradenitis suppurativa.

Tulisokibart adds pipeline evidence

The result gives Merck another clinical milestone as the pharmaceutical group works to broaden its portfolio beyond established oncology products. The study evaluated tulisokibart in patients with moderate to severe hidradenitis suppurativa, making the September 30, 2026 announcement relevant to the companys longer-term pipeline rather than to current sales.

The wider pipeline already carries a measurable financial base. Merck generated USD 16.61 billion of revenue in the second quarter of 2026, up 5.10 percent from the same period a year earlier, according to Yahoo Finance.

Pipeline value meets execution risk

Merck also faces a near-term cost from its recent business development. Under the September 28, 2026 license agreement for SPR2015, the company will pay USD 400.00 million upfront within a potential transaction value of USD 2.13 billion, and the upfront payment will create a third-quarter 2026 charge, StockTitan reported.

Analyst expectations remain divided. Investing.com reported on September 29, 2026 that Bernstein reiterated a Market Perform rating and a USD 105.00 price target, while the same report listed target increases from Berenberg, Guggenheim and Wolfe Research.

Merck stock stays tied to execution

Merck had a market capitalization of USD 359.1 billion on September 30, 2026. The primary-exchange quote showed a USD 73.31 to USD 156.92 52-week range, placing pipeline delivery, regulatory progress and the durability of newer products alongside the companys established revenue base.

At Lang & Schwarz, Merck & Co. stock was trading at EUR 128.34 on October 1, 2026 at 12:03 p.m. CEST, minus 0.04 percent versus the Lang & Schwarz prior close of EUR 128.39 on September 30, 2026. The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.